Associate Professor of Oncologic Sciences
Hematology
Dr. Rami S. Komrokji, MD
|
|
Give Review
Rami Komrokji is an expert in the field of Hematology. He received 3 awards: "Top publication award clinical science", "America's Top Doctors" and "America's Top Doctors for Cancer". Rami Komrokji has written publications. He has 98 publications published with PubMed. The lastest publication is: 'Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemia.' Rami Komrokji accepts Medicare payments and is listed with Medicare.gov.
Publications
- Autoimmune Diseases and Myelodysplastic Syndromes.
- A Multi-Institution Phase 1 Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).
- Outcomes of patients with myelodysplastic Syndromes who achieve stable disease after treatment with hypomethylating agents.
- Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and Acute myeloid leukemia.
- Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic Syndromes treated with azanucleosides.
- Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
- Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic Syndromes.
- Short- and Long-Term Benefits of Lenalidomide Treatment in Patients With Lower-Risk del(5q) Myelodysplastic Syndromes.
- A comprehensive review of pacritinib in myelofibrosis.
- An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myelopro...
- Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
- Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome.
- Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents.
- Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: A Single Institution Experience.
- Hemophagocytic Lymphohistiocytosis in Malignant Hematology: Uncommon but Should Not Be Forgotten?
- Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic Syndromes: Is one model better?
- An international data set for CMML validates prognostic scoring Systems and demonstrates a need for novel prognostication strategies.
- Donor-derived constitutional chromosomal abnormalities after allogeneic hematopoietic Cell transplantation: a single-center experience and a review of the literature.
- A multicenter, Phase II study of maintenance azacitidine in older patients with Acute myeloid leukemia in complete remission after induction chemotherapy.
- Impact of tobacco usage on disease outcome in myelodysplastic Syndromes.
- Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients With myelofibrosis.
- Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
- Current state of prognostication and risk stratification in myelodysplastic Syndromes.
- Myelodysplastic Syndromes, version 2.2015.
- WT1 vaccination in AML and MDS: A pilot trial with synthetic Analog peptides.
- Chronic myelomonocytic Leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.
- A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic Leukemia: observation from a single institution.
- A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes.
- An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in Adults.
- Novel and emerging therapies for the treatment of polycythemia vera.
- Clinical utility of lenalidomide in the treatment of myelodysplastic Syndromes.
- Outcome of patients with low-risk and intermediate-1-risk myelodysplastic Syndrome after hypomethylating agent failure: A Report on Behalf of the MDS Clinical Research...
- Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic Syndrome.
- Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid Leukemia.
- Update on the pharmacotherapy for myelodysplastic Syndromes.
- A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic Syndromes identifying a novel model for response prediction.
- Patients with Myelodysplastic Syndromes Treated with Azacitidine in Clinical Practice: The AVIDA Registry.
- ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic Leukemia.
- A Phase 2, Randomized, Double-blind, Multicenter Study Comparing Siltuximab Plus Best Supportive Care With Placebo Plus Best Supportive Care in Anemic Patients With In...
- The role of pacritinib in the management of myelofibrosis.
- Phase II clinical study of erlotinib for treatment of myelodysplastic Syndromes.
- Phase II, multicenter, randomized, open label trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus cytarabine and daunorubicin in patients With untreat...
- The clinical management of chronic myelomonocytic Leukemia.
- Pre-transplant 5-azacitidine in high-risk myelodysplastic Syndrome.
- Disparity in perceptions of Disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodys...
- Mayo prognostic model for WHO-defined chronic myelomonocytic Leukemia: ASXL1 and spliceosome component mutations and outcomes.
- Prognostic factors and risk models in myelodysplastic Syndromes.
- Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in Acute myeloid leukemia from myelodysplastic syndrome after azanucleosid...
- Deletion 5q MDS: Molecular and therapeutic implications.
- Poor outcome of patients with myelodysplastic Syndrome after azacitidine treatment failure.
- Beyond hypomethylating agents failure in patients with myelodysplastic Syndromes.
- Ruxolitinib for myelofibrosis-an update of its clinical effects.
- Multikinase inhibitors for treating high-risk myelodysplastic Syndromes: can this be brought into clinical practice?
- TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
- There's Risk, and Then There's RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes.
- Phase I clinical trial of oral rigosertib in patients with myelodysplastic Syndromes.
- Gemtuzumab ozogamicin for treatment of newly diagnosed Acute myeloid leukaemia: a systematic review and meta-analysis.
- Myelodysplastic Syndromes: clinical practice guidelines in oncology.
- Higher-risk myelodysplastic Syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?
- Efficacy and safety of lenalidomide in patients with myelodysplastic Syndrome with chromosome 5q deletion.
- Validation of the revised international prognostic scoring system in treated patients with myelodysplastic Syndromes.
- GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic Leukemia.
- Prognostication in myelodysplastic Syndromes: beyond the International Prognostic Scoring System (IPSS).
- Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic Syndrome (MDS) who failed conventional therapy.
- Quality of life outcomes in patients with chronic myeloid Leukemia treated with tyrosine kinase inhibitors: a controlled comparison.
- Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic Syndrome with chromosome 5q deletion.
- Predictive factors of response and survival among chronic myelomonocytic Leukemia patients treated with azacitidine.
- Is it time for 5-azacytidine combinations in high-risk myelodysplastic Syndrome patients?
- A multicenter phase II trial to determine the safety and efficacy of combination therapy With denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and p...
- Outcome of azacitidine treatment in patients with therapy-related Myeloid neoplasms with assessment of prognostic risk stratification models.
- Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic Syndromes.
- Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition.
- Naive T-cells in myelodysplastic Syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency.
- Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic Syndrome.
- Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic Syndromes.
- Advances in the management of myelofibrosis.
- Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic Syndrome.
- Lenalidomide for treatment of myelodysplastic Syndromes.
- Role of lenalidomide in the treatment of myelodysplastic Syndromes.
- Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic Syndrome.
- A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic Syndrome.
- Cutaneous manifestations in CMML: Indication of Disease acceleration or transformation to AML and review of the literature.
- Outcome of Diffuse Large B-Cell Lymphoma in the United States Has Improved Over Time but Racial Disparities Remain: Review of SEER Data.
- Management of lower-risk myelodysplastic Syndromes:the art and evidence.
- Outcomes after induction chemotherapy in patients with Acute myeloid leukemia arising from myelodysplastic syndrome.
- Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for Acute myelogenou...
- Hepatobiliary manifestations of Acute myeloid leukemia.
- Allogeneic hematopoietic Cell transplantation for myelofibrosis: a 10-year experience at single institution.
- Myelodysplastic Syndromes: what a primary care physician needs to know.
- Lenalidomide for treatment of myelodysplastic Syndromes: current status and future directions.
- Myelodysplastic Syndromes classification and risk stratification.
- Lenalidomide in myelodysplastic Syndromes: an erythropoiesis-stimulating agent or more?
- Therapy related CMML: a case report and review of the literature.
- Evolving classifications of the myelodysplastic Syndromes.
- Who is WHO in myelodysplastic Syndromes? Clinical implications of the WHO classification.
- Mini-BEAM and autologous hematopoietic stem-Cell transplant for treatment of post-transplant lymphoproliferative disorders.
- The clinical implications of the World Health Organization's classification of myelodysplastic Syndromes.
Schools
Jordan University School Of Medicine
Case Western University St Vincent Program
Case Western University St Vincent ProgramInternal Medicine
Strong Memorial Hospital University Of Rochester 2004HematologyOncology Strong Memorial Hospital University Of RochesterHematopoietic Stem Cell Transplantation
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Acute Myeloid Leukemia, Adult
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Top publication award clinical science
- America's Top Doctors
- America's Top Doctors for Cancer
Education
-
University of Rochester -
University of Jordan Faculty of Medicine
Hospital
-
H. Lee Moffitt Cancer Center and Research Institute
Drug Facts
| NPI NUMBER | 1942266929 | |
| NPPES Provider LastName | KOMROKJI | |
| NPPES Provider FirstName | RAMI | |
| NPPES Provider ZIPCode | 452194231 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 285.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 12.0 | |
| Percent Opioid Claims | 4.21 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1942266929 |
| Last Name Of The Provider | KOMROKJI |
| First Name Of The Provider | RAMI |
| View All |
Similar Doctors
|
Dr. Kenneth H. Shain, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Paul A. Chervenick, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Loretta S. Loftus, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Khaldoun Almhanna, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Rand W. Altemose, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth A. Byron, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Roohi Ismail-Khan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew A. Fink, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert W. Weaver, MD |
|
Dr. Hyo S. Han, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Monique Z. Sajjad, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Jyotishankar Raychaudhuri, MB
This Doctor is OpenDoctor Recommended.
|